About Cynosure (NASDAQ:CYNO)
Cynosure, Inc. develops, manufactures and markets aesthetic treatment systems that enable plastic surgeons, dermatologists and other medical practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and benign pigmented lesions, remove multi-colored tattoos, revitalize the skin, reduce fat through laser lipolysis, reduce cellulite, clear nails infected by toe fungus, ablate sweat glands and improve women's health. The Company also markets radiofrequency (RF), energy-sourced medical devices for surgical applications, such as facial plastic and general surgery, gynecology, ear, nose, and throat procedures, ophthalmology, oral and maxillofacial surgery, podiatry and proctology. The Company sells its products globally under the Cynosure, Palomar, ConBio and Ellman brand names. Its product portfolio includes single energy source systems, as well as workstations that incorporate two or more different types of lasers or light-based technologies.
Industry, Sector and Symbol
Sub-IndustryHealth Care Equipment
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
EPS (Most Recent Fiscal Year)N/A
Return on Equity0.75%
Return on Assets0.59%
Cynosure (NASDAQ:CYNO) Frequently Asked Questions
What is Cynosure's stock symbol?
Cynosure trades on the NASDAQ under the ticker symbol "CYNO."
How were Cynosure's earnings last quarter?
Cynosure, Inc. (NASDAQ:CYNO) issued its earnings results on Tuesday, July, 26th. The medical equipment provider reported $0.36 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.29 by $0.07. The medical equipment provider had revenue of $110.30 million for the quarter, compared to analysts' expectations of $101.31 million. Cynosure had a return on equity of 0.75% and a net margin of 0.70%. The company's quarterly revenue was up 31.8% on a year-over-year basis. During the same period in the previous year, the firm posted $0.30 EPS. View Cynosure's Earnings History.
Has Cynosure been receiving favorable news coverage?
Press coverage about CYNO stock has been trending somewhat positive on Monday, Accern reports. The research group scores the sentiment of media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cynosure earned a news impact score of 0.01 on Accern's scale. They also gave headlines about the medical equipment provider an impact score of 44.86 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next few days.
How do I buy shares of Cynosure?
Shares of CYNO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cynosure's stock price today?
One share of CYNO stock can currently be purchased for approximately $66.00.
How can I contact Cynosure?
Cynosure's mailing address is 5 Carlisle Rd, WESTFORD, MA 01886-3601, United States. The medical equipment provider can be reached via phone at +1-978-2564200.
MarketBeat Community Rating for Cynosure (CYNO)MarketBeat's community ratings are surveys of what our community members think about Cynosure and other stocks. Vote "Outperform" if you believe CYNO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CYNO will underperform the S&P 500 over the long term. You may vote once every thirty days.